![Three University of Cincinnati researchers wearing lab coats stand at a laboratory counter reviewing data on a computer](https://www.uc.edu/news/articles/2023/02/n21145526/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1675788100619.jpg)
Making pancreatic cancer treatments more effective
NCI to fund research on targeted treatments, processes that drive drug resistance
Pancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.
The American Cancer Society estimates approximately 64,000 Americans will be diagnosed with pancreatic cancer this year, and approximately 50,500 people in the U.S. will die of pancreatic cancer in 2023. While currently the third-leading cause of cancer death in the United States, pancreatic cancer is expected to become the second-leading cause of cancer death by 2030, highlighting the need for new and innovative treatments.
More than 90% of pancreatic cancers are driven by mutations in a certain gene called KRAS. The National Cancer Institute (NCI) has announced an intent to fund research from the University of Cincinnati’s Andrew Waters, PhD, to better understand how to overcome treatment resistance and develop better treatments for KRAS-mutated pancreatic cancer.
KRAS basics
In healthy human cells, the KRAS gene acts as a “light switch” telling cells when to divide.
“In the on position, cells divide. In the off position, cells stop dividing. It is tightly controlled, regulated, and balanced,” said Waters, University of Cincinnati Cancer Center researcher and assistant professor in the UC College of Medicine’s Department of Surgery, Division of Surgical Oncology and Department of Cancer Biology. “When you have a mutation in KRAS, the light switch can’t be turned off, and cells divide uncontrollably. If left unchecked, this can lead to pancreatic cancer.”
The KRAS gene mutations were discovered more than 40 years ago, but it was considered not able to be treated by drugs, or “undruggable,” for decades. Drawn to difficult problems, Waters said the challenge of KRAS appealed to him as an area where he could make a difference.
“Initially when I heard almost all pancreatic cancers had a mutation in the KRAS gene, and it was undruggable, this seemed like somewhere I could potentially contribute,” he said. “As I learned more and more about KRAS, it became a passion of mine, and now I am hooked.”
Andrew Waters uses a microscope to analyze cell samples in his laboratory. Photo/Andrew Higley/UC Marketing + Brand.
The Food and Drug Administration recently approved the first two drugs that target one particular KRAS mutation, but the drugs have a limited use in pancreatic cancer. While the KRAS mutation that the drugs target is common in lung cancers, it is rare in pancreatic cancers.
“About 98% to 99% of KRAS-mutant pancreatic cancer patients have other KRAS mutations and will not benefit from this class of drugs,” said Waters. “We need KRAS drugs that target the KRAS mutations that occur in pancreatic cancer.”
The recently approved KRAS drugs are also limited because like with all targeted therapies, the cancer cells eventually develop resistance to the targeted treatment, Waters said.
“Because we know relapse will occur, we need to identify the resistance mechanisms in pancreatic cancer that drive the relapse in order to develop KRAS inhibitor combination approaches,” he said.
Grace Goodhart, research associate, pipettes samples in Waters' lab. Photo/Andrew Higley/UC Marketing + Brand.
Grant-funded research
The NCI intends to fund Waters’ lab through an approximately $587,000, three-year career development grant. With the funds, Waters will test clinically relevant drugs that target two particular KRAS mutations more commonly found in pancreatic cancer. The drugs being tested are novel, unpublished formulations that will be studied both through cell lines and animal models.
Waters will also study the specific mechanisms within KRAS-mutated pancreatic cancer cells that lead to resistance to targeted treatments. Some of these processes may be similar to resistance processes found in KRAS-mutated lung cancer cells, but Waters said there is growing evidence that each mutation is different.
“Until somewhat recently, almost everyone thought all KRAS mutations are equal,” he said. “I hypothesize different mutations will have some distinct resistance mechanisms. In the era of personalized medicine, this is extremely important, because understanding these mutation-specific resistance mechanisms can potentially guide treatment options in a personalized way.”
With more knowledge on what drugs effectively treat KRAS-mutated pancreatic cancer and what causes drug resistance, the goal is to increase the efficacy and longevity of KRAS-targeted treatments for pancreatic cancer patients.
Andrew Waters and Grace Goodhart collaborate in the lab. Photo/Andrew Higley/UC Marketing + Brand.
Personal motivation
As his work continues, Waters said he continues to be motivated by pancreatic cancer patients, volunteer work with organizations like the Pancreatic Cancer Action Network and the personal effect cancer has had on his life.
“I have lost many family members and close friends to cancer, and some of those people that I lost have been my biggest supporters,” he said.
Waters said his path to joining UC’s faculty has been unconventional, including work at biotech companies and conducting his doctoral research at the Frederick National Laboratory for Cancer Research.
“National laboratories are funded by the federal government so there isn’t a big push to apply for grants and secure additional external funding,” he said. “To receive the best possible score on my first independent grant application from the NCI, arguably the most competitive division of the National Institutes of Health, feels very validating.”
Read about additional pancreatic cancer research at UC led by Krushna Patra.
Featured photo at top: Researchers Krushna Patra, Andrew Waters and Patrick Krause review data. Photo/Andrew Higley/UC Marketing + Brand.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Local 12: 180 UC med students receive white coats, students embark on journey during pandemic
August 9, 2021
The University of Cincinnati College of Medicine welcomed 180 newly admitted first-year students during the college’s 26th annual White Coat Ceremony. The ceremony was held Friday at 10 a.m. at Cincinnati Music Hall, 1241 Elm Street. Each member of the class of 2025 were presented with a white lab coat, symbolizing entry into the medical profession. Local 12 covered the event.
Finding community and building a future
July 9, 2021
As a University of Cincinnati College of Medicine student, Sarah Appeadu, MD, ’21, remembers journaling on the “3 Cs” that got her through medical school: Community, community, community. Now, when she lists the people who supported her through four years of training—the last year in a global pandemic—it keeps growing: her family, her church, her classmates, and the college’s Office of Student Affairs and Office of Diversity, Equity and Inclusion. “I look back and it was such a crucial time to really be nurtured in that way,” she says. “I’m so thankful that I had those people. It shows being around the right people really mattered. That’s my same hope for residency even.”
New York Times: Flint Weighs Scope of Harm to Children Caused by Lead in Water
February 1, 2016
Kim Dietrich, a professor of environmental health at UC's College of Medicine, is quoted in this story on the medical problems that could develop among the thousands of young children exposed to lead-contaminated water in Flint, Mich.
Cancer-Causing Gene Found in Plasma May Help Predict Outcomes for Patients
February 18, 2016
Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients.
UC Receives $1.9 Million to Study Pain
February 15, 2016
Jun-Ming Zhang, MD, of the UC College of Medicine, is the principal investigator of a $1.95 million grant to study the interacting roles of the sympathetic and sensory nervous and immune systems in back and neuropathic pain models.
MD Magazine: Generic Drug Equally Effective in Epilespy
February 22, 2016
Michael Privitera, MD, a professor of neurology at UC's College of Medicine and director of the Epilepsy Center at the UC Neuroscience Institute, is featured in this story about research he led that examined the efficacy of generic drug substitution for epilepsy.
UC to Host Regional Conference for Latino Medical Student Association
February 10, 2016
The University of Cincinnati chapter of the Latino Medical Student Association (LMSA) will host a Midwest regional conference Feb. 26-28, 2016, at the College of Medicine.
Heart Disease Still Top Killer of American Women and Men, Symptoms Differ
February 1, 2016
Women tend to get palpitations, shortness of breath and "sharp" chest pain when suffering heart attacks, explains Stephanie Dunlap, DO, in the UC College of Medicine.
Philosophy Professor Explores Fine Lines Between Right and Wrong in March 29 Public Lecture
March 13, 2016
What distinguishes psychopaths from the rest of us? UC Professor Heidi Maibom offers some clues at a 3:30 p.m. lecture, March 29, in the Russell C. Myers Alumni Center.
Patient Attributes Phase 1 Clinical Trial, Research to Keeping Him Alive
February 29, 2016
Roy Hartman, 74, a Milford, Ohio, resident says what he thought was pneumonia sent him to urgent care on Christmas Eve 2012.